Agilus Diagnostics has introduced the automated Idylla molecular diagnostics system at its Goregaon laboratory in Mumbai, enabling the detection of cancer-related genetic mutations in as little as 2.5 to 3 hours.
Enhancing Speed and Accuracy in Molecular TestingThe Idylla system is a fully integrated, cartridge-based molecular testing platform that streamlines the entire diagnostic process.
Strengthening Precision Medicine CapabilitiesAs per the company press release, the introduction of the Idylla system significantly enhances Agilus Diagnostics’ molecular diagnostics capabilities while supporting faster access to genomic insights for clinicians and patients.
The introduction of the Idylla system at our Goregaon facility significantly enhances our molecular diagnostics capabilities and strengthens our commitment to precision medicine.
With this launch, we continue to strengthen our commitment to providing cutting-edge, high-quality precision diagnostics.”Expanding Access to Advanced Cancer CareWith the addition of the Idylla system, Agilus Diagnostics further strengthens its integrated oncology diagnostics ecosystem.
Agilus Diagnostics has introduced the automated Idylla molecular diagnostics system at its Goregaon laboratory in Mumbai, enabling the detection of cancer-related genetic mutations in as little as 2.5 to 3 hours. This launch marks a major step forward in accelerating clinical decision-making and expanding access to precision oncology across India.
Enhancing Speed and Accuracy in Molecular Testing
The Idylla system is a fully integrated, cartridge-based molecular testing platform that streamlines the entire diagnostic process. It combines sample processing, nucleic acid extraction, amplification, and detection into a single automated workflow. As a result, laboratories can significantly reduce manual intervention and minimize pre-analytical variability.
Consequently, the platform delivers highly accurate and reproducible results much faster than conventional molecular testing methods, which often require several days to generate reports.
Supporting Timely Treatment Decisions
Rapid biomarker identification plays a critical role in oncology, where treatment decisions often depend on the timely detection of actionable genetic mutations. The Idylla platform enables clinicians to quickly identify several clinically relevant biomarkers, including:
EGFR – commonly associated with lung cancer, particularly among Indian and Asian populations
KRAS and NRAS – important markers in colorectal and pancreatic cancers
BRAF – found across multiple tumour types, including melanoma and colorectal cancer
In addition, the platform supports the detection of emerging biomarkers such as MSI (Microsatellite Instability) and IDH1/IDH2, which increasingly guide eligibility for advanced targeted therapies and immunotherapies.
Strengthening Precision Medicine Capabilities
As per the company press release, the introduction of the Idylla system significantly enhances Agilus Diagnostics’ molecular diagnostics capabilities while supporting faster access to genomic insights for clinicians and patients.
Commenting on the launch, Dr. Anand K, MD & CEO, Agilus Diagnostics, said, “The future of oncology lies not just in advanced therapies, but in the ability to deliver fast, accurate diagnoses that can guide treatment decisions in real time. The introduction of the Idylla system at our Goregaon facility significantly enhances our molecular diagnostics capabilities and strengthens our commitment to precision medicine. By enabling rapid access to critical genomic insights, we aim to empower clinicians with timely, actionable information that can improve treatment outcomes and expand access to quality cancer care.”
Delivering Actionable Insights Within Hours
Highlighting the clinical value of the platform, Dr. Kunal Sharma, Vice President and Head – Integrated Onco-Pathology, Agilus Diagnostics, said, “Delivering actionable molecular insights within hours can significantly impact cancer care. The Idylla platform enables rapid detection of key mutations such as EGFR, KRAS, NRAS and BRAF with minimal manual intervention and high analytical performance. This is especially valuable in scenarios where time is critical and tissue samples are limited. With this launch, we continue to strengthen our commitment to providing cutting-edge, high-quality precision diagnostics.”
Expanding Access to Advanced Cancer Care
With the addition of the Idylla system, Agilus Diagnostics further strengthens its integrated oncology diagnostics ecosystem. The platform enables faster and more efficient biomarker-driven treatment pathways, helping clinicians make informed decisions while improving patient access to advanced cancer care.
